These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 22040196)

  • 1. Paliperidone palmitate in a child with autistic disorder.
    Kowalski JL; Wink LK; Blankenship K; Habenicht CD; Erickson CA; Stigler KA; McDougle CJ
    J Child Adolesc Psychopharmacol; 2011 Oct; 21(5):491-3. PubMed ID: 22040196
    [No Abstract]   [Full Text] [Related]  

  • 2. Paliperidone for irritability in autistic disorder.
    Stigler KA; Erickson CA; Mullett JE; Posey DJ; McDougle CJ
    J Child Adolesc Psychopharmacol; 2010 Feb; 20(1):75-8. PubMed ID: 20166801
    [No Abstract]   [Full Text] [Related]  

  • 3. Paliperidone for irritability in adolescents and young adults with autistic disorder.
    Stigler KA; Mullett JE; Erickson CA; Posey DJ; McDougle CJ
    Psychopharmacology (Berl); 2012 Sep; 223(2):237-45. PubMed ID: 22549762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Paliperidone palmitate for schizophrenia.
    Nussbaum AM; Stroup TS
    Schizophr Bull; 2012 Nov; 38(6):1124-7. PubMed ID: 22966147
    [No Abstract]   [Full Text] [Related]  

  • 5. Paliperidone palmitate for refractory and clozapine-resistant schizophrenia.
    Maia-de-Oliveira JP; Nunes EA; Ushirohira JM; Machado-de-Sousa JP; Bressan RA; Hallak JE
    J Neuropsychiatry Clin Neurosci; 2015; 27(1):e14-6. PubMed ID: 25716490
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical pharmacology of paliperidone palmitate a parenteral long-acting formulation for the treatment of schizophrenia.
    Gilday E; Nasrallah HA
    Rev Recent Clin Trials; 2012 Feb; 7(1):2-9. PubMed ID: 22023179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Onset of efficacy and tolerability following the initiation dosing of long-acting paliperidone palmitate: post-hoc analyses of a randomized, double-blind clinical trial.
    Bossie CA; Sliwa JK; Ma YW; Fu DJ; Alphs L
    BMC Psychiatry; 2011 May; 11():79. PubMed ID: 21569242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophrenia.
    Nasrallah HA; Gopal S; Gassmann-Mayer C; Quiroz JA; Lim P; Eerdekens M; Yuen E; Hough D
    Neuropsychopharmacology; 2010 Sep; 35(10):2072-82. PubMed ID: 20555312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of rehospitalization rates and associated costs among patients with schizophrenia receiving paliperidone palmitate or oral antipsychotics.
    Lafeuille MH; Grittner AM; Fortier J; Muser E; Fasteneau J; Duh MS; Lefebvre P
    Am J Health Syst Pharm; 2015 Mar; 72(5):378-89. PubMed ID: 25694413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paliperidone palmitate for schizophrenia.
    Nussbaum AM; Stroup TS
    Cochrane Database Syst Rev; 2012 Jun; (6):CD008296. PubMed ID: 22696377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Maintenance treatment with long-acting injectable antipsychotics: comparing old with new.
    Goff DC
    JAMA; 2014 May; 311(19):1973-4. PubMed ID: 24846032
    [No Abstract]   [Full Text] [Related]  

  • 12. Effects of acute paliperidone palmitate treatment in subjects with schizophrenia recently treated with oral risperidone.
    Sliwa JK; Bossie CA; Ma YW; Alphs L
    Schizophr Res; 2011 Oct; 132(1):28-34. PubMed ID: 21775106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anaphylactoid reaction to paliperidone palmitate extended-release injectable suspension in a patient tolerant of oral risperidone.
    Perry R; Wolberg J; DiCrescento S
    Am J Health Syst Pharm; 2012 Jan; 69(1):40-3. PubMed ID: 22180550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response study.
    Gopal S; Hough DW; Xu H; Lull JM; Gassmann-Mayer C; Remmerie BM; Eerdekens MH; Brown DW
    Int Clin Psychopharmacol; 2010 Sep; 25(5):247-56. PubMed ID: 20389255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of the 3-Month Formulation of Paliperidone Palmitate vs Placebo for Relapse Prevention of Schizophrenia: A Randomized Clinical Trial.
    Berwaerts J; Liu Y; Gopal S; Nuamah I; Xu H; Savitz A; Coppola D; Schotte A; Remmerie B; Maruta N; Hough DW
    JAMA Psychiatry; 2015 Aug; 72(8):830-9. PubMed ID: 25820612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design and rationale of the Paliperidone Palmitate Research in Demonstrating Effectiveness (PRIDE) study: a novel comparative trial of once-monthly paliperidone palmitate versus daily oral antipsychotic treatment for delaying time to treatment failure in persons with schizophrenia.
    Alphs L; Mao L; Rodriguez SC; Hulihan J; Starr HL
    J Clin Psychiatry; 2014 Dec; 75(12):1388-93. PubMed ID: 25375367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophrenia.
    Coppola D; Liu Y; Gopal S; Remmerie B; Samtani MN; Hough DW; Nuamah I; Sulaiman A; Pandina G
    BMC Psychiatry; 2012 Mar; 12():26. PubMed ID: 22455454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. From the Editor-in-Chief's Desk.
    Koplewicz HS
    J Child Adolesc Psychopharmacol; 2015 Aug; 25(6):457. PubMed ID: 26262901
    [No Abstract]   [Full Text] [Related]  

  • 19. Onset and persistence of efficacy by symptom domain with long-acting injectable paliperidone palmitate in patients with schizophrenia.
    Alphs L; Bossie CA; Fu DJ; Ma YW; Kern Sliwa J
    Expert Opin Pharmacother; 2014 May; 15(7):1029-42. PubMed ID: 24754314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment response after relapse in a placebo-controlled maintenance trial in schizophrenia.
    Emsley R; Nuamah I; Hough D; Gopal S
    Schizophr Res; 2012 Jun; 138(1):29-34. PubMed ID: 22446143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.